Population dynamics of tuberculosis treatment: Mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance

International Journal of Tuberculosis and Lung Disease

Volumn 2, Issue 3, 1998, Pages 187-199

  Lipsitch, M ^a   Levin, B R ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Antimicrobial resistance; Isoniazid; Mathematical models; Rifampin; Tuberculosis

Indexed keywords

ISONIAZID; RIFAMPICIN;

ARTICLE; BACTERIAL GROWTH; BACTERIAL MUTATION; BACTERICIDAL ACTIVITY; COMBINATION CHEMOTHERAPY; MATHEMATICAL MODEL; MULTIDRUG RESISTANCE; PATIENT COMPLIANCE; POPULATION DYNAMICS; PREDICTION; PRIORITY JOURNAL; TREATMENT FAILURE; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; HUMANS; MATHEMATICS; MODELS, THEORETICAL; MUTATION; MYCOBACTERIUM TUBERCULOSIS; POPULATION DYNAMICS; TREATMENT REFUSAL; TUBERCULOSIS;

EID: 0031914741     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Combs D L, O'Brien R J, Geiter L J. USPHS Tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and accept-ability. Ann Intern Med 1990; 112: 397-406.
2. David H L. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Applied Microbiol 1970; 20: 810-814.
3. Addington W. Patient compliance: the most serious remaining problem in the control of tuberculosis in the United States. Chest 1979; 76(Suppl): 741-743.
4. Weis S E, Slocum P C, Blais F X, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1179-1184.
5. Bradford W Z, Martin J N, Reingold A L, Schecter G F, Hopewell P C, Small P M. The changing epidemiology of acquired drug-resistant tuberculosis in San Francisco, USA. Lancet 1996; 348: 928-931.
6. Elghoul M T, Joshi R M, Rizghalla T. Primary and acquired drug resistance in Mycobacterium tuberculosis strains in western region of Libyan Arab Jamahiriya. Trop Geogr Med 1989; 41: 304-308.
7. Nolan C M, Williams D L, Cave M D, et al. Evolution of rifampin resistance in human immunodeficiency virus-associated tuberculosis. Am J Respir Crit Care Med 1995, 152: 1067-1071.
8. Mitchison D A, Nunn A J. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423-430.
9. Goble M, Iseman M D, Madsen L A, Waite D, Ackerson L, Horsburgh C R. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-532.
10. Pablos-Mendez A, Knirsch C A, Barr R G, Lerner B H, Frieden T R. Nonadherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med 1997; 102: 164-170.
11. Lipsitch M, Levin B R. The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother 1997; 41: 363-373.
12. Mitchison D A. Basic mechanisms of chemotherapy. Chest 1979; 76(Suppl): 771-781.
13. Iseman M D, Madsen L A. Chronic tuberculous empyema with bronchopleural fistula resulting in treatment failure and progressive drug resistance. Chest 1991; 100: 124-127.
14. Elliott A M, Berning S E, Iseman M D, Peloquin C A. Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema. Tubercle Lung Dis 1995; 76: 463-467.
15. Mitchison D A. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985; 66: 219-225.
16. Jindani A, Aber V R, Edwards E A, Mitchison D A. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121: 939-949.
17. Mitchison D A Drug resistance in mycobacteria. Brit Med Bull 1984; 40: 84-90.
18. Barnett M, Bushby S R M, Mitchison D A. Isoniazid-resistant strains of tubercle bacilli. Lancet 1956; i: 314-320.
19. Dickinson J M, Mitchison D A. Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis 1981; 123: 367-371.
20. Mitchison D A. The Garrod Lecture: Understanding the chemotherapy of tuberculosis - current problems. J Antimicrob Chemother 1992; 29: 477-493.
21. Lutfey M, Della-Latta P, Kapur V, et al. Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS. Am J Respir Crit Care Med 1997; 153: 837-840.
22. Kreiswirth B N. Selective malabsorption and the origin of mono-rifampin-resistant Mycobacterium tuberculosis [author's reply]. Am J Respir Crit Care Med 1996; 154: 1213.
23. Perlman D C, Salomon N. Selective malabsorption and the origin of mono-rifampin-resistant Mycobacterium tuberculosis [letter]. Am J Respir Crit Care Med 1996; 154: 1213.
24. Peloquin C A, MacPhee A A, Berning S E. Malabsorption of antimycobacterial medications. N Engl J Med 1993; 328: 1122.
25. Di Perri G, Vento S, Cazzadori A, Bonora S, Concia E. Multidrug-resistant tuberculosis in patients with AIDS. Arch Intern Med 1995; 155: 1452-1453.
26. Shriner K A, Mathisen G E, Goetz M B. Comparison of mycobacterial lymphadenitis among persons infected with human immunodeficiency virus and seronegative controls. Clin Infect Dis 1992; 15: 601-605.
27. Relkin F, Aranda C P, Garay S M, Smith R, Berkowitz K A, Rom W N. Pleural tuberculosis and HIV infection. Chest 1994; 105: 1338-1341.
28. Brindle R J, Nunn P P, Githui W, Allen B W, Gathua S, Waiyaki P. Quantitative bacillary response to treatment in HIV-associated pulmonary tuberculosis. Am Rev Respir Dis 1993; 147: 958-961.
29. Alpert P L, Munsiff S S, Gourevitch M N, Greenberg B, Klein R S. A prospective study of tuberculosis and human immunodeficiency virus infection: clinical manifestations and factors associated with survival. Clin Infect Dis 1997; 24: 661-668.
30. Bradford W Z, Hopewell P C, Small P M. M. tuberculosis drug resistance in AIDS: authors' reply. Lancet 1997; 349: 61-62.